Disclosed is a therapy protocol for treating patients having metastatic bone disease, hypercalcemia of malignancy and/or metabolic bone disease by administering an intravenous, citrate-buffered formulation of alendronate which is isotonic with human blood.
申请公布号
WO9605842(A1)
申请公布日期
1996.02.29
申请号
WO1995US10583
申请日期
1995.08.21
申请人
MERCK & CO., INC.;BRENNER, GERALD, S.;GHANNAM, MUSA, M.